Alexion Pharmaceuticals Inc

Find Ratings Reports
ALXN : NASDAQ : Health Care
$122.96 | %
Today's Range: 121.34 - 123.45
Avg. Daily Volume: 2185500.0
12/02/16 - 4:00 PM ET

Financial Analysis


ALEXION PHARMACEUTICALS INC's gross profit margin for the third quarter of its fiscal year 2016 has decreased when compared to the same period a year ago. Sales and net income have grown, and although the growth in revenues has outpaced the average competitor within the industry, the net income growth has not. ALEXION PHARMACEUTICALS INC is extremely liquid. Currently, the Quick Ratio is 2.38 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year, indicating deteriorating cash flow.

At the same time, stockholders' equity ("net worth") has remained virtually unchanged only increasing by 3.04% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q3 FY16 Q3 FY15
Net Sales ($mil)799.11666.64
EBITDA ($mil)0.0247.51
EBIT ($mil)226.75197.79
Net Income ($mil)94.34-183.76


Balance Sheet Q3 FY16 Q3 FY15
Cash & Equiv. ($mil)1312.871458.49
Total Assets ($mil)13293.4613153.02
Total Debt ($mil)3476.773649.6
Equity ($mil)8504.18252.87


Profitability Q3 FY16 Q3 FY15
Gross Profit Margin81.6693.86
EBITDA Margin0.037.12
Operating Margin28.3729.67
Sales Turnover0.220.19
Return on Assets2.81.75
Return on Equity4.382.8
Debt Q3 FY16 Q3 FY15
Current Ratio3.113.23
Debt/Capital0.290.31
Interest Expense24.8119.97
Interest Coverage9.149.9


Share Data Q3 FY16 Q3 FY15
Shares outstanding (mil)224.22225.99
Div / share0.00.0
EPS0.42-0.81
Book value / share37.9336.52
Institutional Own % n/a n/a
Avg Daily Volume2073674.01983172.0

Valuation


HOLD. ALEXION PHARMACEUTICALS INC's P/E ratio indicates a significant premium compared to an average of 34.27 for the Biotechnology industry and a significant premium compared to the S&P 500 average of 25.16. Conducting a second comparison, its price-to-book ratio of 3.24 indicates a premium versus the S&P 500 average of 2.79 and a significant discount versus the industry average of 11.17. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
ALXN 74.53 Peers 34.27   ALXN NA Peers 28.50

Premium. A higher P/E ratio than its peers can signify a more expensive stock or higher growth expectations.

ALXN is trading at a significant premium to its peers.

 

Neutral. The P/CF ratio is the stock’s price divided by the sum of the company's cash flow from operations. It is useful for comparing companies with different capital requirements or financing structures.

Ratio not available.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
ALXN 21.76 Peers 40.16   ALXN 0.13 Peers 0.44

Discount. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth expectations.

ALXN is trading at a significant discount to its peers.

 

Discount. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

ALXN trades at a significant discount to its peers.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
ALXN 3.24 Peers 11.17   ALXN 34.14 Peers 2.62

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

ALXN is trading at a significant discount to its peers.

 

Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

ALXN is expected to have an earnings growth rate that significantly exceeds its peers.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
ALXN 9.33 Peers 170.51   ALXN 18.03 Peers 481.80

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

ALXN is trading at a significant discount to its industry on this measurement.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

ALXN significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades